
## Fan Daiming

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3576522/publications.pdf Version: 2024-02-01



FAN DAIMING

#	Article	IF	CITATIONS
1	lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nature Medicine, 2017, 23, 1331-1341.	15.2	352
2	Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. Journal of Hepatology, 2011, 54, 78-88.	1.8	291
3	Biological properties and clinical applications of berberine. Frontiers of Medicine, 2020, 14, 564-582.	1.5	182
4	Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut, 2018, 67, 2156-2168.	6.1	132
5	Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. Journal of Hepatology, 2017, 67, 508-516.	1.8	131
6	Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer. Oncotarget, 2016, 7, 76076-76086.	0.8	61
7	Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer. Nature Communications, 2019, 10, 2037.	5.8	55
8	Methylenetetrahydrofolate reductase <scp><i>C677T</i></scp> gene mutation and hyperhomocysteinemia in Budd–Chiari syndrome and portal vein thrombosis: A systematic review and metaâ€analysis of observational studies. Hepatology Research, 2014, 44, E480-98.	1.8	28
9	Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. Radiology, 2017, 285, 999-1010.	3.6	25
10	TIPSS for variceal bleeding in patients with idiopathic nonâ€cirrhotic portal hypertension: comparison with patients who have cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 926-939.	1.9	24
11	Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 736-746.	3.7	24
12	miR-125b Promotes Colorectal Cancer Migration and Invasion by Dual-Targeting CFTR and CGN. Cancers, 2021, 13, 5710.	1.7	16
13	Insights into the role of ERp57 in cancer. Journal of Cancer, 2021, 12, 2456-2464.	1.2	15
14	Comparative pharmacoproteomics reveals potential targets for berberine, a promising therapy for colorectal cancer. Biochemical and Biophysical Research Communications, 2020, 525, 244-250.	1.0	13
15	Silencing of ER-resident oxidoreductase PDIA3 inhibits malignant biological behaviors of multidrug-resistant gastric cancer. Acta Biochimica Et Biophysica Sinica, 2021, 53, 1216-1226.	0.9	7
16	Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China. Liver International, 2023, 43, 18-33.	1.9	7
17	Evaluation of MT Family Isoforms as Potential Biomarker for Predicting Progression and Prognosis in Gastric Cancer. BioMed Research International, 2019, 2019, 1-15.	0.9	3
18	Expression and subcellular location of COX-2 in human gastric cancer cells. Chinese Journal of Digestive Diseases, 2001, 2, 61-64.	1.1	1

#	Article	IF	CITATIONS
19	Selective killing of gastric cancer cells by monoclonal antibody conjugated with a chain of ricin. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1989, 1, 34-38.	0.7	0
20	Cytotoxicity of indirect immunotoxin mediated by anti-gastric cancer monoclonal antibodies on tumor cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1990, 2, 31-34.	0.7	0